Intelligencia Uses Artificial Intelligence To Provide Data Clarity For Pharma, Bridging The Gap Between Innovation And Risk Reduction

In this episode of the Making Impact Series, Helen is joined by Vangelis Vergetis, co-founder of Intelligencia. Vangelis has spent the last 15 years in healthcare, particularly on the interface between life sciences, technology, and data science. Prior to founding Intelligencia, Vangelis spent about a dozen years as a consultant at McKinsey and at Hakluyt, working with clients across different areas within healthcare. He is a board member and member of the executive committee at the Alliance for AI in Healthcare (AAIH), and a member of the advisory board for Cornell’s department of Computer & Information Science (CIS).

Intelligencia helps bring novel therapies to patients faster and more efficiently by applying Data Science to drug development. Based on a unique wealth of proprietary and expertly curated data, Intelligencia has been pioneering the use of Machine Learning algorithms to assess, quantify, and reduce the risk of clinical development.

0:59 - Vangelis’s background & origin story

3:24 - Focusing on risk & drug development

7:20 - The question of building the product vs buying the product

10:15 - The main value proposition and benefits for utilizing Intelligencia

13:12 - The ultimate impact that Intelligencia is having on patients & their journeys

15:49 - Where Intelligencia is as a startup

18:18 - What impact Vangelis is looking to make in the industry

Resources

Intelligencia: https://www.intelligencia.ai/

Connect With ODAIA

Blog: www.odaia.ai/making-impact/intelligencia-uses-artificial-intelligence-to-provide-data-clarity-for-pharma-bridging-the-gap-between-innovation-and-risk-reduction

Website: https://www.odaia.ai/

LinkedIn: https://www.linkedin.com/company/odaiaintelligence/

Contact Us: https://www.odaia.ai/contact